<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00677222</url>
  </required_header>
  <id_info>
    <org_study_id>AMI-07-001</org_study_id>
    <nct_id>NCT00677222</nct_id>
  </id_info>
  <brief_title>Safety Study of AMI MultiStem® to Treat Heart Attacks</brief_title>
  <official_title>A Phase I, Multicenter, Dose-Escalation Trial Evaluating the Safety of Allogeneic AMI MultiStem® in Patients With Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Athersys, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Angiotech Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Athersys, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if escalating doses of AMI MultiStem® delivered by&#xD;
      catheter can safely be given to patients that have had a recent heart attack treated with&#xD;
      stent implantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mortality rates associated with acute myocardial infarction (AMI) have significantly&#xD;
      decreased over the past 2 decades. Beginning first with thrombolytic therapy for AMI, and&#xD;
      more recently with growing acceptance and availability of primary percutaneous coronary&#xD;
      intervention (PCI) for ST-elevation AMI, the mortality rates of this devastating ischemic&#xD;
      event have decreased from almost 15% in clinical trials in the late 1980's to &lt;5% in recent&#xD;
      primary percutaneous coronary intervention trials. Though AMI-related mortality has been&#xD;
      reduced, AMI survival is often accompanied by significant loss of function that may lead to&#xD;
      subsequent treatments, congestive heart failure (CHF) and reduction in quality of life. A&#xD;
      cell therapy that could reduce the damage associated with AMI and positively affect heart&#xD;
      function would provide substantial benefits to the AMI patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of adverse events during the first 24 hours after administration of AMI MultiStem® and post acute adverse events up to 30 days following AMI</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of longer term safety and cardiac function over 12 months following AMI</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Registry Arm -standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AMI MultiStem®</intervention_name>
    <description>AMI MultiStem® administered via catheter into peri-vascular space of the target vessel, 2-5 days post PCI. There will be 3 dose escalation cohorts, 6 patients per cohort.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of either sex 18-85 years of age&#xD;
&#xD;
          -  Women of childbearing potential or less than 2 years postmenopausal agree to use of&#xD;
             adequate contraception during the study&#xD;
&#xD;
          -  Patients with the first time diagnosis of ST elevation myocardial infarction&#xD;
&#xD;
          -  Acute myocardial infarction (ST elevation in at least two leads &gt;0.2 mV in V1, V2 or&#xD;
             V3 or &gt;0.1 mV in other leads), treated by one of the following: either&#xD;
&#xD;
          -  Acute PCI with stent implantation&#xD;
&#xD;
          -  With thrombolysis within 12 hr of symptom onset followed by PCI with stent&#xD;
             implantation within 24 hr after Thrombolysis&#xD;
&#xD;
          -  Maximal creatine kinase elevation &gt;400 U/l with significant membrane-bound fraction&#xD;
             (&gt;6%)or troponin &gt;2X ULN&#xD;
&#xD;
          -  Decreasing levels of CK/CK-MB or troponin following reperfusion&#xD;
&#xD;
          -  Successful acute PCI/stent implantation (residual stenosis visually &lt;30% and TIMI flow&#xD;
             &gt;2). Absence of severe disorder of the microcirculation (e.g. pulsatile flow pattern,&#xD;
             systolic flow reversal) at the time of administration of the trial therapy&#xD;
&#xD;
          -  Significant regional wall motion abnormality in left ventricular angiogram or&#xD;
             transthoracic echocardiogram ≤48 hours post PCI&#xD;
&#xD;
          -  LVEF between 30 and 45% by LV gram after the primary PCI or transthoracic&#xD;
             echocardiogram ≤48 hours post PCI&#xD;
&#xD;
          -  Willing and able to comply with the scheduled visits, treatment, laboratory tests and&#xD;
             other study related procedures.&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior cardiovascular history&#xD;
&#xD;
          -  Mechanical complications of the index acute myocardial infarction including but not&#xD;
             limited to rupture of the mitral valve with resultant development of mitral&#xD;
             regurgitation, rupture of the left ventricular free wall and rupture of the&#xD;
             interventricular septum&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Known allergy to contrast agents&#xD;
&#xD;
          -  Known allergy or religious objections to bovine or porcine products&#xD;
&#xD;
          -  History of malignancy of any type except non-melanoma skin cancer&#xD;
&#xD;
          -  Presence of major hematological conditions or laboratory abnormalities (low hemoglobin&#xD;
             (&lt;10 gm/dl), - WBC (&lt;3,000 cells/mm2) or platelet count (&lt;100,000 cells/mm3))&#xD;
&#xD;
          -  Prothrombin time (PT) &gt; 1x ULN&#xD;
&#xD;
          -  Partial thromboplastin time (PTT) &gt; 1x ULN&#xD;
&#xD;
          -  Presence of chronic systemic inflammatory disorders that requires ongoing therapy&#xD;
&#xD;
          -  Previous autologous, allogeneic bone marrow or peripheral stem cell transplant&#xD;
&#xD;
          -  Prior solid organ transplantation&#xD;
&#xD;
          -  Immune system compromise including but not limited to history of human&#xD;
             immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C (HCV) infection.&#xD;
&#xD;
          -  Prior participation in any other study involving investigational pharmacological&#xD;
             agents(s), devices or marketed products within 30 days prior to planned AMI MultiStem®&#xD;
             administration&#xD;
&#xD;
          -  Life expectancy of six months or less&#xD;
&#xD;
          -  Current alcohol or substance abuse&#xD;
&#xD;
          -  Ongoing systemic infection&#xD;
&#xD;
          -  Renal function: Serum creatinine &gt;2 mg/dL or creatinine clearance ≤50 mL/min&#xD;
&#xD;
          -  Hepatic function: Screening ALT and AST ≥3x upper limit of normal for the laboratory&#xD;
             or total bilirubin ≥2.0 mg/dL (exception: acceptable if patient is identified with pre&#xD;
             existing condition e.g. Gilbert's disease that will contribute to baseline elevations&#xD;
             of bilirubin)&#xD;
&#xD;
          -  Other serious medical or psychiatric illness that, in the investigator's opinion,&#xD;
             would not permit the patient to be managed according to the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Penn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Warren Sherman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Care Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Health</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamot Medical Center</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>May 12, 2008</study_first_submitted>
  <study_first_submitted_qc>May 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2008</study_first_posted>
  <last_update_submitted>May 10, 2012</last_update_submitted>
  <last_update_submitted_qc>May 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myocardial Infarction, Heart Attack</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

